LeMaitre Vascular, Inc.

Welcome to the Limit Vascular Q2 2021 Financial Results Conference Call. As a reminder, today's call is being recorded. At this time, I would like to turn the call over to Mr. JJ Pellegrino, Chief Financial Officer of Limit Vascular. Please go ahead, sir.

Thank you, Operator. Good afternoon, and thank you for joining us on our Q2 2021 Conference Call. With me on today's call are Chairman and CEO George LeMay and our President Dave Roberts. Before we begin, I'll read our safe harbor statement. Today we will make some forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, the accuracy of which is subject to risks and uncertainties. Wherever possible, we will try to identify those forward-looking statements by using words such as believe, expect, anticipate, pursue, forecast, and similar expressions. Our forward-looking statements are based on our estimates and assumptions as of today, July 29, 2021, and should not be relied upon as representing our estimates or views on any subsequent date. Please refer to the cautionary statement regarding forward-looking information and the risk factors in our most recent 10-K and subsequent SEC filings, including the disclosures of factors that could cause results to differ materially from those expressed or implied. During this call, we will discuss non-GAAP financial measures, which include EBITDA and non-GAAP outstanding debt. A reconciliation of GAAP and non-GAAP measures is discussed in this call, is contained in the associated press release, and is available in the investor relations section of our website, www.lemate.com. I'll now turn the call over to George Lemaitre.

Thanks, JJ. On today's call, I'll cover three topics. Number one, COVID's impact on our employees. Number two, record Q2 sales, And finally, number three, rebuilding our Salesforce. First, I'd like to review COVID's impact on our team. 38 employees have been infected since the pandemic began with all now recovered. Thanks to the availability of vaccines, our US and UK staff returned to the office on June 21st and our EU and Canadian staff did the same on July 26th. And we continue to observe health and safety measures in our facilities. We posted record sales of 40.7 million in Q2, up 64% versus the COVID-affected Q2 2020. Sales grew 83% in the Americas, 36% in EMEA, and 30% in APAC. By product, autograph sales were 6.7 million in Q2, and there were several records. Valvetomes, carotid chunks, carotid patches, and allografts. APAC benefited in Q2 from $250,000 of Japanese Xenosure sales, and we expect to submit Xenosure trial results to the Chinese FDA by October. Chinese Xenosure approval is likely in 2023 or 2024. We ended Q2 with 88 sales reps. Despite 27 open requisitions, sales rep hiring has been slow. We intend to return to our pre-COVID high watermark of 112 reps. Meanwhile, we're expanding our warehouses in England, Italy, and Japan in order to improve customer connections and speed up order fulfillment. By October, we'll be shipping from our warehouses to hospitals in eight of our nine largest markets. With that, I'll turn the call over to JJ.